AIM: To investigate the relationships between Type 2 diabetes mellitus (DM2) and the risk of hepatocellular carcinoma (HCC). METHODS: We studied the association between DM2 and HCC in a large case-control study that enrolled 465 consecutive Caucasian patients with HCC (78.3% males, mean age 68.5 +/- 8.9 years) compared with an age and sex matched control group of 490 subjects. RESULTS: Prevalence of DM2 was significantly higher in HCC patients (31.2% vs 12.7%; OR = 3.12, 95% CI: 2.22-4.43) and in HCC cases with alcohol abuse. DM2 has been diagnosed before the appearance of HCC in 84.1% of diabetic HCC subjects with mean duration of 141.5 mo, higher in cases treated with insulin than in those with oral antidiabetic agents (171.5 vs 118.7 mo). Compared to controls, males DM2 with HCC were more frequently treated with insulin (38.1% vs 17.6%, P = 0.009) and with sulfonylurea with or without metformin than with diet with or without metformin (84% vs 68.3%, P = 0.049). CONCLUSION: DM2 in our patients is associated with a 3-fold increase risk of HCC. In most of our cases DM2 pre-existed to HCC. Patients with DM2 and chronic liver disease, particularly insulin treated males, should be considered for HCC close surveillance programs.
AIM: To investigate the relationships between Type 2 diabetes mellitus (DM2) and the risk of hepatocellular carcinoma (HCC). METHODS: We studied the association between DM2 and HCC in a large case-control study that enrolled 465 consecutive Caucasian patients with HCC (78.3% males, mean age 68.5 +/- 8.9 years) compared with an age and sex matched control group of 490 subjects. RESULTS: Prevalence of DM2 was significantly higher in HCC patients (31.2% vs 12.7%; OR = 3.12, 95% CI: 2.22-4.43) and in HCC cases with alcohol abuse. DM2 has been diagnosed before the appearance of HCC in 84.1% of diabetic HCC subjects with mean duration of 141.5 mo, higher in cases treated with insulin than in those with oral antidiabetic agents (171.5 vs 118.7 mo). Compared to controls, males DM2 with HCC were more frequently treated with insulin (38.1% vs 17.6%, P = 0.009) and with sulfonylurea with or without metformin than with diet with or without metformin (84% vs 68.3%, P = 0.049). CONCLUSION:DM2 in our patients is associated with a 3-fold increase risk of HCC. In most of our cases DM2 pre-existed to HCC. Patients with DM2 and chronic liver disease, particularly insulin treated males, should be considered for HCC close surveillance programs.
Authors: P Lindblad; W H Chow; J Chan; A Bergström; A Wolk; G Gridley; J K McLaughlin; O Nyrén; H O Adami Journal: Diabetologia Date: 1999-01 Impact factor: 10.122
Authors: H O Adami; W H Chow; O Nyrén; C Berne; M S Linet; A Ekbom; A Wolk; J K McLaughlin; J F Fraumeni Journal: J Natl Cancer Inst Date: 1996-10-16 Impact factor: 13.506
Authors: Steven S Coughlin; Eugenia E Calle; Lauren R Teras; Jennifer Petrelli; Michael J Thun Journal: Am J Epidemiol Date: 2004-06-15 Impact factor: 4.897
Authors: Laura J Niedernhofer; J Scott Daniels; Carol A Rouzer; Rachel E Greene; Lawrence J Marnett Journal: J Biol Chem Date: 2003-05-29 Impact factor: 5.157
Authors: D T Silverman; M Schiffman; J Everhart; A Goldstein; K D Lillemoe; G M Swanson; A G Schwartz; L M Brown; R S Greenberg; J B Schoenberg; L M Pottern; R N Hoover; J F Fraumeni Journal: Br J Cancer Date: 1999-08 Impact factor: 7.640
Authors: Elizabeth A Atchison; Gloria Gridley; J Daniel Carreon; Michael F Leitzmann; Katherine A McGlynn Journal: Int J Cancer Date: 2011-02-01 Impact factor: 7.396
Authors: Diego Garcia-Compean; Joel Omar Jaquez-Quintana; Jose Alberto Gonzalez-Gonzalez; Hector Maldonado-Garza Journal: World J Gastroenterol Date: 2009-01-21 Impact factor: 5.742
Authors: Massimiliano Balbi; Valter Donadon; Michela Ghersetti; Silvia Grazioli; Giovanni Della Valentina; Rita Gardenal; Maria Dal Mas; Pietro Casarin; Giorgio Zanette; Cesare Miranda; Paolo Cimarosti Journal: Int J Environ Res Public Health Date: 2010-03-29 Impact factor: 3.390
Authors: Valter Donadon; Massimiliano Balbi; Michela Ghersetti; Silvia Grazioli; Antonio Perciaccante; Giovanni Della Valentina; Rita Gardenal; Maria Dal Mas; Pietro Casarin; Giorgio Zanette; Cesare Miranda Journal: World J Gastroenterol Date: 2009-05-28 Impact factor: 5.742